Page 1501 - Williams Hematology ( PDFDrive )

1476 Part X: Malignant Myeloid Diseases Chapter 89: Chronic Myelogenous Leukemia and Related Disorders 1477

149. Collins SJ, Kubonishi I, Miyoshi I, Groudine MT: Altered transcription of the c-abl 182. Melo JV: The diversity of BCR-ABL fusion proteins and their relationship to leukemia
oncogene in K562 and other chronic myelogenous leukemia cells. Science 225:72, phenotype. Blood 88:2375, 1996.
1984. 183. Rubinstein R, Purves LR: A novel BCR-ABL rearrangement in a Philadelphia chro-
150. Leibowitz D, Cubbon RM, Bank A: Increased expression of a novel c-abl related RNA mosome-positive chronic myelogenous leukaemia variant with thrombocythaemia.
in K562 cells. Blood 65:526, 1985. Leukemia 12:230, 1998.
151. Konopka JB, Watanabe SM, Witte ON: An alteration of the human c-abl protein in 184. Hochhaus A, Reither A, Skladny H, et al: A novel BCR-ABL fusion gene (e6a2) in
K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37:1035, 1984. a patient with Philadelphia chromosome-negative chronic myelogenous leukemia.
152. Konopka JB, Watanabe SM, Singer JW, et al: Cell lines and clinical isolates derived Blood 88:2236, 1996.
from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with 185. Briz M, Vilches C, Cabrera R, et al: Typical chronic myelogenous leukemia with e19a2
a common structural alteration. Proc Natl Acad Sci U S A 82:1810, 1985. junction BCR/ABL transcript. Blood 90:5024, 1997.
153. Stam K, Heisterkamp N, Grosveld G, et al: Evidence of a new chimeric bcr/c-abl 186. McLaughlin J, Chianese E, Witte ON: In vitro transformation of immature hemopoi-
mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromo- etic cells by P210 bcr/abl oncogene product of the Philadelphia chromosome. Proc
some. N Engl J Med 313:1429, 1985. Natl Acad Sci U S A 84:6558, 1987.
154. Ben-Neriah Y, Daley GQ, Mes-Masson AM, et al: The chronic myelogenous leuke- 187. Daley GQ, McLaughlin J, Witte ON, Baltimore D: The CML-specific P210 bcr/abl
mia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233:212, protein, unlike v-abl, does not transform NIH/3T3 fibroblasts. Science 237:532, 1987.
1985. 188. Elefanty AG, Hariharan IK, Cory S: Bcr-abl, the hallmark of chronic myeloid leukaemia
155. Maxwell SA, Kurzrock R, Parson SJ, et al: Analysis of P210bcr/abl tyrosine protein in man, induces multiple haemopoietic neoplasms in mice. EMBO J 9:1069, 1990.
kinase activity in various subtypes of Philadelphia chromosome-positive cells from 189. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in
chronic myelogenous leukemia patients. Cancer Res 47:1731, 1987. mice by the p210bcr/abl gene of the Philadelphia chromosome. Science 247:824, 1990.
157. Xu DQ, Galibert F: Restriction fragment length polymorphism caused by a deletion 190. Voncken JW, Morris C, Pattengale P, et al: Clonal development and karyotype evolu-
within the human c-abl gene (ABL). Proc Natl Acad Sci U S A 83:3447, 1986. tion during leukemogenesis of BCR/ABL transgenic mice. Blood 79:1029, 1992.
158. Popenoe DW, Schaefer-Rego K, Mears JC, et al: Frequent and extensive deletion dur- 191. Gishizky ML, Johnson-White J, Witte O: Efficient transplantation of BCR-ABL-
ing the 9,22 translocation in CML. Blood 68:1123, 1986. induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci U
159. Shtivelman E, Gale RP, Dreazen O, et al: Bcr-abl RNA in patients with chronic granu- S A 90:3755, 1993.
locytic leukemia. Blood 69:971, 1987. 192. Daley GQ: Animal models of BCR/ABL-induced leukemias. Leuk Lymphoma 11:57,
160. McWhirter JR, Wang JJ: Activation of tyrosine kinase and microfilament-binding func- 1993.
tions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol 11:1553, 1991. 193. Voncken JW, Kaartinen V, Pattengale PK, et al: BCR/ABL P210 and P190 cause dis-
161. Bernards A, Rubin CM, Westbrook CA, et al: The first intron in the human c-abl gene tinct leukemia in transgenic mice. Blood 86:4603, 1995.
is at least 200 kilobases long and is the target for translocations in chronic myeloge- 194. Honda H, Oda H, Suzuki T, et al: Development of acute lymphoblastic leukemia and
nous leukemia. Mol Cell Biol 7:3231, 1987. myeloproliferative disorder in transgenic mice expressing p210bcr/abl: A novel trans-
162. Eisenberg A, Silver R, Soper L, et al: The location of breakpoints within the breakpoint genic model for human Ph 1-positive leukemias. Blood 91:2067, 1998.
cluster region (bcr) of chromosome 22 in chronic myeloid leukemia. Leukemia 2:642, 195. Pear WS, Miller JP, Xu L, et al: Efficient and rapid induction of a chronic myelogenous
1988. leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced
163. Collins SJ: Breakpoints on chromosomes 9 and 22 in Philadelphia chromosome- bone marrow. Blood 92:3780, 1998.
positive chronic myelogenous leukemia. J Clin Invest 78:1392, 1986. 196. Honda M, Ohno S, Takahashi T, et al: Establishment, characterization, and chromo-
164. Heisterkamp N, Stam K, Groffen J, et al: Structural organization of the bcr gene and its somal analysis of new leukemic cell lines derived from MT/p210/bcr/abl transgenic
role in the Ph1 translocation. Nature 315:758, 1985. mice. Exp Hematol 26:188, 1998.
165. Gao LM, Goldman J: Long-range mapping of the normal BCR gene. Leukemia 5:555, 197. Zhang X, Ren R: Bcr-Abl efficiency induces in a myeloproliferative disease and pro-
1991. duction of excess interleukin-3 and granulocyte-macrophage colony-stimulating fac-
166. Melo JV: BCR-ABL gene variants. Baillieres Clin Haematol 10:203, 1997. tor in mice: A novel model for chronic myelogenous leukemia. Blood 92:3829, 1998.
167. Saglio G, Pane F, Gottardi E, et al: Consistent amounts of acute leukemia-associated 198. Elefanty AG, Corsy S: Bcr-abl-induced cell lines can switch from mast cell to erythroid
P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients or myeloid differentiation in vitro. Blood 79:1271, 1992.
at diagnosis. Blood 87:1075, 1996. 199. Van Etten RA: Pathogenesis and treatment of Ph+ leukemia: Recent insights from
168. Honda H, Oda H, Suzuki T, et al: Development of acute lymphoblastic leukemia and mouse models. Curr Opin Hematol 8:224, 2001.
myeloproliferative disorder in transgenic mice expressing p210bcr/abl: A novel trans- 200. Bose S, Deininger M, Goora-Tybor J, et al: The presence of typical and atypical BCR-
genic model for human Ph1-positive leukemias. Blood 91:2067, 1998. ABL fusion genes in leukocytes of normal individuals: Biological significance and
169. Maru Y, Witte ON: The BCR gene encodes a novel serine/threonine kinase activity implications for the assessment of minimal residual disease. Blood 92:3362, 1998.
within a single exon. Cell 67:459, 1991. 201. Hirai HS, Tanaka M, Azuma Y, et al: Transforming genes in human leukemia cells.
170. Muller AJ, Young JC, Pendergast A-M, et al: BCR first exon sequences specifically acti- Blood 66:1371, 1985.
vate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive 202. Clarkson BD, Strife A, Wisniewski D, et al: New understanding of the pathogenesis of
human leukemia. Mol Cell Biol 11:1785, 1991. CML: A prototype of early neoplasia. Leukemia 11:1404, 1997.
171. Diekmann D, Brill S, Garrett MD, et al: BCR encodes a GTPase-activating protein for 203. Verfaillie CM: Chronic myelogenous leukemia: From pathogenesis to therapy. J
p21rac. Nature 351:400, 1991. Hematother 8:3, 1999.
172. Melo JV, Gordon DE, Goldman JM: The ABL-BCR fusion gene is expressed in chronic 204. Pasternak G, Hochhaus A, Schultheis B, Hehlmann R: Chronic myelogenous leuke-
myeloid leukemia. Blood 81:158, 1993. mia: Molecular and cellular aspects. J Cancer Res Clin Oncol 124:643, 1998.
173. Bartram CR, de Klein A, Hagemeijer A, et al: Translocation of the human c-abl onco- 205. Gotoh A, Broxmeyer HE: The function of BCR/ABL and related protooncogenes.
gene correlates with the presence of a Philadelphia chromosome in chronic myelo- Curr Opin Hematol 4:3, 1997.
cytic leukaemia. Nature 306:277, 1983. 206. Sattler M, Salgia R: Activation of hematopoietic growth factor signal transduction
174. Selleri L, Narni F, Emilia G, et al: Philadelphia-positive chronic myeloid leukemia with pathways by the human oncogene BCR/ABL. Cytokine Growth Factor Rev 8:63, 1997.
a chromosome 22 breakpoint outside the breakpoint cluster region. Blood 70:1659, 207. Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al: Phosphatidylinositol-3 kinase
1987. activity is regulated by BCR/ABL and is required for the growth of Philadelphia chro-
175. Mohamed AN, Koppitch F, Varterasian M, et al: BCR/ABL fusion located on chromo- mosome-positive cells. Blood 86:726, 1995.
some 9 in chronic myeloid leukemia with a masked Ph chromosome. Genes Chromo- 208. Skorski T, Nieborowska-Skorska M, Szczylik C, et al: C-RAF-1 serine/threonine
somes Cancer 13:133, 1995. kinase is required in BCR/ABL-dependent and normal hematopoiesis. Cancer Res
176. Morris C, Jeffs A, Smith T, et al: BCR gene recombines with genomically distinct sites 55:2275, 1995.
on band 11Q13 in complex BCR-ABL translocations of chronic myeloid leukemia. 209. Goga A, McLaughlin J, Afar DE, et al: Alternative signals to RAS for hematopoietic
Oncogene 12:677, 1996. transformation by the BCR-ABL oncogene. Cell 82:981, 1995.
177. Andreasson P, Johansson B, Carlsson M, et al: BCR/ABL-negative chronic myeloid 210. Salgia R, Uemura N, Okuda K, et al: CRKL links p210BCR/ABL with paxillin in
leukemia with ETV6/ABL fusion. Genes Chromosomes Cancer 20:299, 1997. chronic myelogenous leukemia cells. J Biol Chem 270:29145, 1995.
178. Rozman C, Urbano-Ispizua A, Cervantes F, et al: Analysis of the clinical relevance of 211. De Jong R, ten Hoeve J, Heisterkamp N, Groffen J: Crkl is complexed with tyrosine-
the breakpoint location within M-BCR and the type of chimeric mRNA in chronic phosphorylated Cbl in Ph-positive leukemia. J Biol Chem 270:21468, 1995.
myelogenous leukemia. Leukemia 9:1104, 1995. 212. Salgia R, Pisick E, Sattler M, et al: P130CAS forms a signalling complex with the adap-
179. Verschraegen CF, Kantarjian HM, Hirsch-Ginsberg C, et al: The breakpoint cluster ter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J
region site in patients with Philadelphia chromosome-positive chronic myelogenous Biol Chem 271:25198, 1996.
leukemia. Clinical, laboratory, and prognostic correlations. Cancer 76:992, 1995. 213. Sattler M, Griffin JD: Molecular mechanisms of transformation by the BCR-ABL
180. Zaccaria A, Martinelli G, Testoni N, et al: Does the type of BCR/ABL junction predict oncogene. Semin Hematol 40:4, 2003.
the survival of patients with Ph1-positive chronic myeloid leukemia? Leuk Lymphoma 214. Melo JV, Deininger MW: Biology of chronic myelogenous-signaling pathways of initi-
16:231, 1995. ation and transformation. Hematol Oncol Clin North Am 18:545, 2004.
181. Ohno T, Hada S, Sugiyama T, et al: Chronic myeloid leukemia with minor bcr break- 215. Wong S, Witte ON: The BCR-ABL story: Bench to bedside and back. Annu Rev Immu-
point developed hybrid type of blast crisis. Am J Hematol 57:320, 1998. nol 22:247, 2004.

Kaushansky_chapter 89_p1437-1490.indd 1476 9/18/15 3:42 PM